Concepts (250)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Pulmonary Disease, Chronic Obstructive | 18 | 2019 | 3832 | 1.79 | Why? |
| Adrenergic beta-2 Receptor Agonists | 6 | 2019 | 142 | 1.39 | Why? |
| Nitric Oxide | 4 | 2019 | 769 | 1.36 | Why? |
| Bronchodilator Agents | 8 | 2019 | 444 | 1.16 | Why? |
| Formoterol Fumarate | 4 | 2018 | 61 | 1.11 | Why? |
| Scleroderma, Systemic | 3 | 2019 | 583 | 1.00 | Why? |
| Glycopyrrolate | 2 | 2018 | 51 | 0.84 | Why? |
| Stress, Mechanical | 1 | 2019 | 143 | 0.78 | Why? |
| Salmeterol Xinafoate | 1 | 2018 | 28 | 0.75 | Why? |
| Breath Tests | 2 | 2019 | 338 | 0.74 | Why? |
| Lung Diseases, Interstitial | 3 | 2019 | 1476 | 0.73 | Why? |
| Continuous Positive Airway Pressure | 3 | 2021 | 1187 | 0.69 | Why? |
| Walk Test | 2 | 2018 | 461 | 0.69 | Why? |
| Muscarinic Antagonists | 5 | 2019 | 176 | 0.65 | Why? |
| Ventilator Weaning | 1 | 2021 | 536 | 0.61 | Why? |
| Respiratory Therapy | 1 | 2021 | 918 | 0.52 | Why? |
| Pulmonary Medicine | 1 | 2018 | 706 | 0.45 | Why? |
| Hypertension, Pulmonary | 2 | 2018 | 970 | 0.44 | Why? |
| Noninvasive Ventilation | 2 | 2021 | 2329 | 0.44 | Why? |
| Hypoxia | 3 | 2020 | 3626 | 0.43 | Why? |
| Bronchoscopy | 1 | 2018 | 991 | 0.41 | Why? |
| Adrenal Cortex Hormones | 5 | 2019 | 6537 | 0.40 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2020 | 1671 | 0.39 | Why? |
| Administration, Inhalation | 7 | 2019 | 1647 | 0.37 | Why? |
| Thrombophilia | 1 | 2020 | 1935 | 0.34 | Why? |
| Oxygen | 1 | 2020 | 3715 | 0.32 | Why? |
| Scopolamine Derivatives | 1 | 2005 | 10 | 0.32 | Why? |
| Lung Diseases | 3 | 2021 | 2361 | 0.32 | Why? |
| Omalizumab | 2 | 2019 | 158 | 0.31 | Why? |
| Ethanolamines | 1 | 2005 | 71 | 0.29 | Why? |
| Psoriasis | 1 | 2018 | 1739 | 0.27 | Why? |
| Pneumonia | 2 | 2021 | 5652 | 0.27 | Why? |
| Forced Expiratory Volume | 7 | 2019 | 632 | 0.27 | Why? |
| Inspiratory Capacity | 2 | 2018 | 47 | 0.26 | Why? |
| Budesonide | 1 | 2005 | 192 | 0.26 | Why? |
| Anti-Asthmatic Agents | 2 | 2019 | 427 | 0.25 | Why? |
| Exercise Tolerance | 2 | 2018 | 634 | 0.24 | Why? |
| Spirometry | 4 | 2018 | 524 | 0.24 | Why? |
| Respiratory Function Tests | 5 | 2020 | 1755 | 0.21 | Why? |
| Tetracyclines | 1 | 2020 | 82 | 0.20 | Why? |
| Partial Pressure | 1 | 2020 | 279 | 0.20 | Why? |
| Hospitalization | 3 | 2021 | 54280 | 0.20 | Why? |
| Head Protective Devices | 1 | 2020 | 163 | 0.20 | Why? |
| Hospital Mortality | 2 | 2021 | 22087 | 0.20 | Why? |
| Residual Volume | 1 | 2018 | 45 | 0.19 | Why? |
| Italy | 15 | 2021 | 38444 | 0.19 | Why? |
| Thoracentesis | 1 | 2018 | 23 | 0.19 | Why? |
| Respiratory Insufficiency | 4 | 2021 | 7301 | 0.19 | Why? |
| Beclomethasone | 1 | 2018 | 32 | 0.18 | Why? |
| Expert Systems | 1 | 2018 | 42 | 0.18 | Why? |
| Software Design | 1 | 2018 | 87 | 0.18 | Why? |
| Interferon-gamma Release Tests | 1 | 2020 | 253 | 0.18 | Why? |
| Vital Capacity | 4 | 2017 | 399 | 0.18 | Why? |
| Chi-Square Distribution | 1 | 2021 | 961 | 0.18 | Why? |
| Cross-Over Studies | 2 | 2018 | 867 | 0.18 | Why? |
| Thoracoscopy | 1 | 2018 | 113 | 0.17 | Why? |
| Pleural Diseases | 1 | 2018 | 68 | 0.17 | Why? |
| Tropanes | 1 | 2017 | 18 | 0.17 | Why? |
| Proof of Concept Study | 1 | 2020 | 696 | 0.17 | Why? |
| Decision Trees | 1 | 2019 | 441 | 0.17 | Why? |
| Facial Dermatoses | 1 | 2021 | 222 | 0.17 | Why? |
| Vagus Nerve | 1 | 2017 | 57 | 0.17 | Why? |
| Blood Gas Analysis | 1 | 2020 | 893 | 0.16 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.16 | Why? |
| Immune System Diseases | 1 | 2021 | 410 | 0.16 | Why? |
| Sympathetic Nervous System | 1 | 2017 | 111 | 0.16 | Why? |
| Latent Tuberculosis | 1 | 2020 | 324 | 0.16 | Why? |
| Prospective Studies | 8 | 2021 | 43301 | 0.16 | Why? |
| Dermatitis, Occupational | 1 | 2021 | 310 | 0.15 | Why? |
| Withholding Treatment | 2 | 2019 | 798 | 0.15 | Why? |
| Asthma | 4 | 2019 | 4383 | 0.15 | Why? |
| Eosinophilia | 1 | 2019 | 292 | 0.15 | Why? |
| Compassionate Use Trials | 1 | 2020 | 632 | 0.15 | Why? |
| Off-Label Use | 1 | 2020 | 553 | 0.15 | Why? |
| Early Medical Intervention | 1 | 2019 | 487 | 0.15 | Why? |
| Exhalation | 1 | 2019 | 441 | 0.15 | Why? |
| Severity of Illness Index | 5 | 2020 | 48226 | 0.14 | Why? |
| Humans | 46 | 2021 | 930598 | 0.14 | Why? |
| Fibromyalgia | 1 | 2017 | 174 | 0.14 | Why? |
| Glucocorticoids | 3 | 2018 | 4431 | 0.14 | Why? |
| Aged | 18 | 2021 | 215776 | 0.14 | Why? |
| Drug Therapy | 1 | 2017 | 280 | 0.14 | Why? |
| Bronchiectasis | 1 | 2018 | 312 | 0.13 | Why? |
| Walking | 1 | 2018 | 442 | 0.13 | Why? |
| Area Under Curve | 1 | 2021 | 2564 | 0.13 | Why? |
| Awareness | 1 | 2018 | 529 | 0.13 | Why? |
| Specialization | 1 | 2017 | 432 | 0.12 | Why? |
| Blood Glucose Self-Monitoring | 1 | 2018 | 791 | 0.12 | Why? |
| Molecular Structure | 1 | 2017 | 1539 | 0.12 | Why? |
| Male | 22 | 2021 | 367725 | 0.12 | Why? |
| Aspirin | 1 | 2020 | 1043 | 0.11 | Why? |
| Double-Blind Method | 2 | 2018 | 5988 | 0.11 | Why? |
| Female | 22 | 2021 | 380317 | 0.11 | Why? |
| Middle Aged | 20 | 2021 | 270681 | 0.11 | Why? |
| Smokers | 1 | 2017 | 550 | 0.11 | Why? |
| Physical Therapy Modalities | 1 | 2020 | 1090 | 0.11 | Why? |
| Respiration Disorders | 1 | 2017 | 526 | 0.11 | Why? |
| Exercise Test | 1 | 2017 | 911 | 0.10 | Why? |
| Drug Combinations | 4 | 2019 | 3852 | 0.10 | Why? |
| Hyperglycemia | 1 | 2021 | 1363 | 0.10 | Why? |
| General Practitioners | 1 | 2017 | 568 | 0.10 | Why? |
| Meta-Analysis as Topic | 1 | 2017 | 1289 | 0.10 | Why? |
| Quality of Life | 4 | 2018 | 9820 | 0.10 | Why? |
| Survival Rate | 2 | 2021 | 9206 | 0.10 | Why? |
| Drug Therapy, Combination | 3 | 2018 | 7268 | 0.10 | Why? |
| ROC Curve | 1 | 2021 | 6024 | 0.09 | Why? |
| Pneumonia, Viral | 7 | 2020 | 243684 | 0.09 | Why? |
| Consensus | 2 | 2020 | 6345 | 0.09 | Why? |
| Seasons | 1 | 2021 | 4071 | 0.09 | Why? |
| Exercise | 2 | 2018 | 6771 | 0.09 | Why? |
| Skin Diseases | 2 | 2021 | 2509 | 0.08 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.08 | Why? |
| Precision Medicine | 1 | 2017 | 1477 | 0.08 | Why? |
| Monitoring, Physiologic | 1 | 2018 | 1956 | 0.08 | Why? |
| Comorbidity | 4 | 2018 | 34796 | 0.08 | Why? |
| Blood Glucose | 1 | 2021 | 3642 | 0.08 | Why? |
| Disease Progression | 4 | 2018 | 13580 | 0.08 | Why? |
| Community-Acquired Infections | 1 | 2018 | 2328 | 0.08 | Why? |
| Tiotropium Bromide | 1 | 2005 | 46 | 0.08 | Why? |
| Lung | 3 | 2020 | 31049 | 0.07 | Why? |
| Sleep Wake Disorders | 1 | 2017 | 1463 | 0.07 | Why? |
| Dyspnea | 1 | 2018 | 3847 | 0.07 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.07 | Why? |
| Randomized Controlled Trials as Topic | 3 | 2018 | 10649 | 0.07 | Why? |
| Patient Selection | 1 | 2019 | 4560 | 0.07 | Why? |
| Fluoroquinolones | 1 | 2005 | 235 | 0.07 | Why? |
| Diabetes Mellitus, Type 1 | 1 | 2018 | 1969 | 0.07 | Why? |
| Fibrin Fibrinogen Degradation Products | 1 | 2020 | 5993 | 0.07 | Why? |
| Length of Stay | 1 | 2021 | 11042 | 0.06 | Why? |
| Cohort Studies | 3 | 2021 | 36005 | 0.06 | Why? |
| Disease Outbreaks | 2 | 2021 | 27595 | 0.06 | Why? |
| Practice Patterns, Physicians' | 2 | 2017 | 4927 | 0.06 | Why? |
| Masks | 2 | 2021 | 8528 | 0.06 | Why? |
| Lung Neoplasms | 1 | 2018 | 3228 | 0.06 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.05 | Why? |
| Hospitals | 1 | 2020 | 11793 | 0.05 | Why? |
| Pilot Projects | 2 | 2018 | 5182 | 0.05 | Why? |
| Practice Guidelines as Topic | 3 | 2019 | 15421 | 0.05 | Why? |
| Patient Acceptance of Health Care | 1 | 2018 | 5002 | 0.05 | Why? |
| Inflammation | 2 | 2021 | 13255 | 0.05 | Why? |
| Intensive Care Units | 3 | 2020 | 29594 | 0.05 | Why? |
| Anticoagulants | 1 | 2021 | 9563 | 0.05 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.05 | Why? |
| Illness Behavior | 1 | 2018 | 76 | 0.05 | Why? |
| Antiviral Agents | 3 | 2021 | 41703 | 0.05 | Why? |
| Lung Volume Measurements | 1 | 2018 | 115 | 0.05 | Why? |
| Insulin-Secreting Cells | 1 | 2021 | 273 | 0.05 | Why? |
| Surveys and Questionnaires | 4 | 2019 | 43792 | 0.05 | Why? |
| Predictive Value of Tests | 3 | 2019 | 9537 | 0.05 | Why? |
| Peroneal Nerve | 1 | 2017 | 13 | 0.04 | Why? |
| Glomerulonephritis | 1 | 2021 | 226 | 0.04 | Why? |
| Chest Wall Oscillation | 1 | 2017 | 17 | 0.04 | Why? |
| Uveitis | 1 | 2021 | 233 | 0.04 | Why? |
| Plethysmography, Whole Body | 1 | 2017 | 33 | 0.04 | Why? |
| Catecholamines | 1 | 2017 | 66 | 0.04 | Why? |
| Spectrum Analysis | 1 | 2017 | 112 | 0.04 | Why? |
| Clinical Trials as Topic | 1 | 2017 | 7330 | 0.04 | Why? |
| Adult | 9 | 2021 | 244371 | 0.04 | Why? |
| Expert Testimony | 1 | 2021 | 658 | 0.04 | Why? |
| Pulmonary Ventilation | 1 | 2018 | 152 | 0.04 | Why? |
| Nitrogen | 1 | 2017 | 106 | 0.04 | Why? |
| SARS Virus | 1 | 2020 | 13021 | 0.04 | Why? |
| Treatment Outcome | 5 | 2019 | 51732 | 0.04 | Why? |
| Critical Care | 1 | 2020 | 14081 | 0.04 | Why? |
| Personal Protective Equipment | 1 | 2021 | 15978 | 0.04 | Why? |
| Pandemics | 8 | 2021 | 389249 | 0.04 | Why? |
| Sample Size | 1 | 2018 | 518 | 0.04 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2018 | 8811 | 0.04 | Why? |
| Carbon Monoxide | 1 | 2017 | 167 | 0.04 | Why? |
| Polysomnography | 1 | 2017 | 296 | 0.04 | Why? |
| Neural Conduction | 1 | 2017 | 261 | 0.04 | Why? |
| Autonomic Nervous System | 1 | 2017 | 148 | 0.04 | Why? |
| Oximetry | 1 | 2020 | 658 | 0.04 | Why? |
| Insulin Resistance | 1 | 2021 | 669 | 0.04 | Why? |
| Delayed-Action Preparations | 1 | 2017 | 291 | 0.04 | Why? |
| Vaccination | 1 | 2021 | 19050 | 0.04 | Why? |
| Drug Resistance | 1 | 2018 | 395 | 0.04 | Why? |
| Evidence-Based Medicine | 2 | 2019 | 3228 | 0.04 | Why? |
| Nasal Polyps | 1 | 2018 | 221 | 0.04 | Why? |
| Biomarkers | 1 | 2018 | 23361 | 0.03 | Why? |
| Oseltamivir | 1 | 2018 | 583 | 0.03 | Why? |
| Cardiorespiratory Fitness | 1 | 2018 | 313 | 0.03 | Why? |
| Tidal Volume | 1 | 2017 | 565 | 0.03 | Why? |
| Delphi Technique | 1 | 2019 | 1257 | 0.03 | Why? |
| Health Status | 2 | 2018 | 3259 | 0.03 | Why? |
| Risk Factors | 2 | 2020 | 71621 | 0.03 | Why? |
| Anti-Infective Agents | 1 | 2005 | 1766 | 0.03 | Why? |
| Influenza, Human | 1 | 2018 | 10779 | 0.03 | Why? |
| Adrenergic beta-Antagonists | 1 | 2017 | 465 | 0.03 | Why? |
| Aged, 80 and over | 5 | 2021 | 88759 | 0.03 | Why? |
| Respiratory Rate | 1 | 2017 | 691 | 0.03 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.03 | Why? |
| Patient Acuity | 1 | 2020 | 1755 | 0.03 | Why? |
| Eosinophils | 1 | 2019 | 848 | 0.03 | Why? |
| Age Factors | 3 | 2018 | 21039 | 0.03 | Why? |
| Europe | 2 | 2021 | 12702 | 0.03 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 1 | 2020 | 1165 | 0.03 | Why? |
| Reproducibility of Results | 2 | 2018 | 11304 | 0.03 | Why? |
| Activities of Daily Living | 1 | 2018 | 1530 | 0.03 | Why? |
| Early Diagnosis | 1 | 2019 | 2443 | 0.02 | Why? |
| Phenotype | 1 | 2021 | 4037 | 0.02 | Why? |
| Equipment Design | 1 | 2020 | 3095 | 0.02 | Why? |
| Immunity | 1 | 2020 | 2651 | 0.02 | Why? |
| Poland | 1 | 2017 | 2368 | 0.02 | Why? |
| Medication Adherence | 1 | 2018 | 1270 | 0.02 | Why? |
| Leukocyte Count | 1 | 2019 | 3178 | 0.02 | Why? |
| Patient Compliance | 1 | 2018 | 1468 | 0.02 | Why? |
| Lymphopenia | 1 | 2020 | 2669 | 0.02 | Why? |
| Animals | 1 | 2017 | 78931 | 0.02 | Why? |
| Quality Improvement | 1 | 2020 | 2435 | 0.02 | Why? |
| Cost of Illness | 1 | 2018 | 1903 | 0.02 | Why? |
| Dose-Response Relationship, Drug | 1 | 2017 | 3776 | 0.02 | Why? |
| Retrospective Studies | 4 | 2020 | 105322 | 0.02 | Why? |
| Obesity | 2 | 2018 | 7388 | 0.02 | Why? |
| Multivariate Analysis | 1 | 2018 | 5440 | 0.02 | Why? |
| Bronchitis, Chronic | 1 | 2005 | 15 | 0.02 | Why? |
| Prevalence | 2 | 2020 | 25773 | 0.02 | Why? |
| Blood Pressure | 1 | 2017 | 2198 | 0.02 | Why? |
| Patient Satisfaction | 1 | 2018 | 2517 | 0.02 | Why? |
| Antirheumatic Agents | 1 | 2020 | 3023 | 0.02 | Why? |
| Internationality | 1 | 2018 | 3297 | 0.02 | Why? |
| Respiration, Artificial | 2 | 2021 | 22116 | 0.02 | Why? |
| Time Factors | 2 | 2018 | 31397 | 0.02 | Why? |
| Rheumatic Diseases | 1 | 2021 | 2675 | 0.02 | Why? |
| Prognosis | 2 | 2019 | 32490 | 0.02 | Why? |
| Emergencies | 1 | 2020 | 4095 | 0.02 | Why? |
| Respiratory Tract Infections | 1 | 2005 | 6817 | 0.02 | Why? |
| Referral and Consultation | 1 | 2021 | 4816 | 0.02 | Why? |
| Guideline Adherence | 1 | 2017 | 2309 | 0.02 | Why? |
| Smoking | 1 | 2018 | 3358 | 0.02 | Why? |
| Cough | 1 | 2018 | 4891 | 0.02 | Why? |
| Inflammatory Bowel Diseases | 1 | 2021 | 3209 | 0.02 | Why? |
| Chronic Disease | 1 | 2018 | 5139 | 0.02 | Why? |
| Databases, Factual | 1 | 2018 | 6248 | 0.02 | Why? |
| Electrocardiography | 1 | 2017 | 3957 | 0.02 | Why? |
| Disease Management | 1 | 2020 | 6841 | 0.01 | Why? |
| Germany | 1 | 2017 | 9196 | 0.01 | Why? |
| France | 1 | 2017 | 12074 | 0.01 | Why? |
| Sex Factors | 1 | 2017 | 11014 | 0.01 | Why? |
| Young Adult | 2 | 2021 | 93724 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2018 | 17020 | 0.01 | Why? |
| Diabetes Mellitus | 1 | 2021 | 8207 | 0.01 | Why? |
| Antibodies, Monoclonal, Humanized | 1 | 2020 | 9335 | 0.01 | Why? |
| Spain | 1 | 2017 | 15545 | 0.01 | Why? |
| Case-Control Studies | 1 | 2017 | 17671 | 0.01 | Why? |
| Drug Resistance, Bacterial | 1 | 2005 | 1414 | 0.01 | Why? |
| Bacteria | 1 | 2005 | 1897 | 0.01 | Why? |
| Infection Control | 1 | 2020 | 23131 | 0.01 | Why? |
| Cross-Sectional Studies | 1 | 2018 | 53120 | 0.01 | Why? |
| Adolescent | 1 | 2018 | 86841 | 0.01 | Why? |